Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Clinical Treatment and Prognosis of Breast Cancer
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Treatment and Prognosis of Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 630

Special Issue Editors

Dr. Roxana Popescu

E-Mail Website1 Website2
Guest Editor
Cell and Molecular Biology Department, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, 300041 Timișoara, Romania
Interests: cell biology; molecular biology; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Ionut Marcel Cobec

E-Mail Website
Guest Editor
1. ANAPATMOL Research Center, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
2. Clinic of Obstetrics and Gynecology, Klinikum Freudenstadt, 72250 Freudenstadt, Germany
Interests: breast cancer; therapy; personalized therapy; gynecologic oncology; gynecologic cancers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the upcoming Special Issue Clinical Treatment and Prognosis of Breast Cancer. This Issue aims to bring together high-quality research and clinical insights that advance our understanding of modern breast cancer therapies, personalized treatment strategies, prognosis, survival and long-term patient outcomes.

Breast cancer remains one of the most common and complex malignancies worldwide, and continuous innovation in its treatment is essential. We welcome original research articles, comprehensive reviews, and clinical case studies that explore novel treatment approaches, predictive biomarkers, surgical techniques, patient management, and emerging therapies.

Our goal is to create a multidisciplinary platform for exchanging knowledge that can influence current practices and future directions in oncology. Your expertise and clinical experience would make a valuable contribution to this Special Issue.

We look forward to receiving your submissions and to collaborating on this important topic that affects millions globally.

With best regards,

Dr. Roxana Popescu
Dr. Ionut Marcel Cobec
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • targeted therapy
  • personalized therapy
  • alternative approach
  • tumor biology
  • gynecologic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 657 KB  
Review
Trastuzumab–Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies
by Erica Quaquarini, Federica Luelli, Angioletta Lasagna, Gianpiero Rizzo, Lorenzo Perrone, Simone Figini, Raffaella Achille and Paolo Pedrazzoli
Cancers 2025, 17(21), 3505; https://doi.org/10.3390/cancers17213505 - 30 Oct 2025
Abstract
Background: Trastuzumab–deruxtecan (T-DXd), a new-generation antibody drug conjugate, has greatly improved the survival and clinical benefit rates of patients affected by advanced HER2-positive/HER2-low breast cancer according to the results of controlled clinical trials with a manageable safety profile. Data from randomized clinical trials [...] Read more.
Background: Trastuzumab–deruxtecan (T-DXd), a new-generation antibody drug conjugate, has greatly improved the survival and clinical benefit rates of patients affected by advanced HER2-positive/HER2-low breast cancer according to the results of controlled clinical trials with a manageable safety profile. Data from randomized clinical trials can provide valuable information for the management of patients in everyday clinical practice, including those who would typically be excluded from such trials due to not meeting the inclusion criteria. Methods: In this narrative review, we describe and discuss real-world studies in the literature on the use of T-Dxd in HER2-positive and HER2-low MBC patients, providing a critical analysis of the specific settings of clinical interest. Results: Using a PubMed search, we identified nine real-world studies on T-DXd that are available in the literature. A total of 7146 patients have been included in these retrospective studies. A total of 5/9 studies also included HER2-low MBC patients. In the majority of cases, patients had high disease burden with lung and liver involvement. We then reviewed and discussed clinical areas of interest, including heavily pretreated patients, poor performance status, HER2-positive versus HER2-low disease, brain metastasis, elderly patients, lung toxicity, safety profile, and dose modifications. Conclusions: Our analysis confirms the activity of the drug described in real-world studies and shows a favorable safety profile, with manageable adverse effects. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognosis of Breast Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop